Followers | 14 |
Posts | 807 |
Boards Moderated | 0 |
Alias Born | 04/24/2009 |
Wednesday, July 23, 2014 11:10:42 AM
Oncology agreement with AstraZeneca expanded A second, expanded agreement with AstraZeneca in the field of
cancer medicine using Starpharma’s proprietary DEP™
technology is a strong validation of the interest in the Company’s
drug delivery technology. The agreement follows an earlier
agreement with AstraZeneca to access Starpharma’s delivery
technology. The new agreement will see the application of
Starpharma’s technology to a cancer drug, from AstraZeneca’s
pipeline.
“As a leading discovery-led company this alliance represents
an exciting collaboration with an Australian-based company to
combine the oncology treatments of tomorrow that AstraZeneca is
developing using innovative delivery mechanisms,” said Mark
Fladrich, Managing Director, AstraZeneca Australia.
Under the new agreement, AstraZeneca will provide funding
for a pre-clinical stage cancer research program to be
conducted jointly.
http://www.starpharma.com/assets/asxannouncements/140612_Shareholder_Update_JUNE_1.pdf
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM